指南与共识炎症性肠病

AGA 中重度溃疡性结肠炎药物治疗临床实践动态指南

AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
指南 / 共识 · Gastroenterology · 2024-01-01

美国胃肠病协会(AGA)采用 GRADE 框架制定中重度溃疡性结肠炎(UC)药物治疗动态指南,共提出 14 条推荐,涵盖生物制剂与小分子药物的选择、联合免疫调节剂的使用、5-氨基水杨酸停药及早期进阶治疗等,并指出知识空白与未来研究方向。

要点

  • 成人中重度 UC 门诊患者,AGA 推荐使用英夫利西单抗、戈利木单抗、维得利珠单抗、托法替布、乌帕替尼、乌司奴单抗、奥扎尼莫德、依曲莫德、瑞莎珠单抗和古塞奇尤单抗,建议使用阿达木单抗、非戈替尼和米吉珠单抗而非不治疗。
  • 未接触过进阶治疗者,AGA 建议选用高效药物或中等效药物而非低效药物(如阿达木单抗);曾暴露于 1 种及以上进阶治疗(尤其 TNF-α 拮抗剂)者,AGA 建议选用高效或中等效药物而非低效药物。
  • AGA 建议反对硫嘌呤单药用于诱导缓解,但建议硫嘌呤单药用于维持(通常为糖皮质激素诱导的)缓解而非不治疗;建议反对甲氨蝶呤单药用于诱导或维持缓解。

核心结论

  • 本指南为中重度 UC 患者的药物治疗提供了以患者为中心的综合方法。

研究设计与样本

  • 美国胃肠病协会(AGA)动态指南,由内容专家和指南方法学家组成的多学科小组采用 GRADE 框架制定。

主要发现

  • AGA 指南小组共提出 14 条推荐。
  • 在成人中重度 UC 门诊患者中,AGA 推荐使用英夫利西单抗、戈利木单抗、维得利珠单抗、托法替布、乌帕替尼、乌司奴单抗、奥扎尼莫德、依曲莫德、瑞莎珠单抗和古塞奇尤单抗,建议使用阿达木单抗、非戈替尼和米吉珠单抗而非不治疗。
  • 在未接触过进阶治疗的患者中,AGA 建议使用高效药物(如英夫利西单抗、维得利珠单抗、奥扎尼莫德、依曲莫德、乌帕替尼、瑞莎珠单抗和古塞奇尤单抗)或中等效药物(如戈利木单抗、乌司奴单抗、托法替布、非戈替尼和米吉珠单抗)而非低效药物(如阿达木单抗)。
  • 在曾暴露于 1 种或以上进阶治疗(特别是肿瘤坏死因子(TNF)-α 拮抗剂)的患者中,AGA 建议使用高效药物(如托法替布、乌帕替尼和乌司奴单抗)或中等效药物(如非戈替尼、米吉珠单抗、瑞莎珠单抗和古塞奇尤单抗)而非低效药物(如阿达木单抗、维得利珠单抗、奥扎尼莫德和依曲莫德)。
  • 在成人中重度 UC 门诊患者中,AGA 建议反对硫嘌呤单药用于诱导缓解,但建议硫嘌呤单药用于维持(通常为糖皮质激素诱导的)缓解而非不治疗。

关键数值与推荐

  • AGA 建议反对甲氨蝶呤单药用于诱导或维持缓解。
  • 在成人中重度 UC 门诊患者中,AGA 建议英夫利西单抗、阿达木单抗和戈利木单抗联合免疫调节剂而非相应单药治疗。
  • AGA 对非 TNF 拮抗剂生物制剂联合免疫调节剂对比非 TNF 生物制剂单药治疗不作推荐支持或反对。
  • 在 TNF 拮抗剂联合免疫调节剂治疗下无糖皮质激素临床缓解至少 6 个月的 UC 患者中,AGA 建议反对停用 TNF 拮抗剂,但对停用免疫调节剂不作推荐支持或反对。
  • 在已失败 5-氨基水杨酸并已升级至免疫调节剂或进阶治疗的成人中重度 UC 门诊患者中,AGA 建议停用 5-氨基水杨酸。

临床怎么用

  • 本指南推荐与建议基于 GRADE 框架,用于指导成人中重度 UC 门诊患者的药物治疗选择。
  • 指南小组提出了这些药物最佳使用的关键实施考虑,并识别了若干知识空白和未来研究领域。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC). METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations on the pharmacological management of moderate-to-severe UC. RESULTS: The AGA guideline panel made 14 recommendations. In adult outpatients with moderate-to-severe UC, the AGA recommends the use of infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, and guselkumab, and suggests the use of adalimumab, filgotinib, and mirikizumab over no treatment. In patients who are naïve to advanced therapies, the AGA suggests using a higher-efficacy medication (eg, infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, and guselkumab) or an intermediate-efficacy medication (eg, golimumab, ustekinumab, tofacitinib, filgotinib, and mirikizumab) rather than a lower-efficacy medication (eg, adalimumab). In patients who have previously been exposed to 1 or more advanced therapies, particularly tumor necrosis factor (TNF)-α antagonists, the AGA suggests using a higher-efficacy medication (eg, tofacitinib, upadacitinib, and ustekinumab) or an intermediate-efficacy medication (eg, filgotinib, mirikizumab, risankizumab, and guselkumab) rather than a lower-efficacy medication (eg, adalimumab, vedolizumab, ozanimod, and etrasimod). In adult outpatients with moderate-to-severe UC, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests against using methotrexate monotherapy, for induction or maintenance of remission. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab, adalimumab, and golimumab in combination with an immunomodulator over corresponding monotherapy. However, the AGA makes no recommendation in favor of, or against, the use of non-TNF antagonist biologics in combination with an immunomodulator over non-TNF biologic alone. In patients with UC who are in corticosteroid-free clinical remission for at least 6 months on combination therapy of TNF antagonists and an immunomodulator, the AGA suggests against withdrawal of TNF antagonists, but makes no recommendation in favor of, or against, withdrawing immunomodulators. In adult outpatients with moderate-to-severe UC, who have failed 5-aminosalicylates, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-aminosalicylates. Finally, in adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies and/or immunomodulator therapy, rather than gradual step-up after failure of 5-aminosalicylates. The panel also proposed key implementation considerations for optimal use of these medications and identified several knowledge gaps and areas for future research. CONCLUSIONS: This guideline provides a comprehensive, patient-centered approach to the pharmacological management of patients with moderate-to-severe UC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singh S, Loftus EV, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024. PMID: 39572132. doi:10.1053/j.gastro.2024.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。